|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded |
Company Size: |
50 Employees In BC (50 Total)
50 In BC (50 Total)
|
Year Founded: |
2005 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
development, commercialization, reprofiling, drugs, Diabetic Macular Edema
|
Profile Views: |
1,119 Company Profile Views |
|
|
iCo Therapeutics is a "Search and Development" company. By focusing efforts on development instead of research, iCo's business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Subsequent development of these therapeutics may include drug delivery technologies-such as sustained release or biodegradable matrices to extend patent coverage.
There is a significant decrease in development risk associated with targeting existing drugs, including:
- Reduced risk of adverse events since clinical testing and systemic use in humans has already been established.
- Scale-up and manufacturing issues have already been addressed since clinical grade material has been made.
- The target and mechanism of action has been identified.
|
|
|
Date |
Type |
Amount |
Investors |
Date |
Type |
Amount |
Investors |
|
|
Want More iCo Therapeutics Inc. News? 1 2
|
Next »
|
|
|
|
|
Nov 25, 2019
|
iCo Therapeutics Partners with Top 15 Biotech Company Alexion Pharmaceuticals for the Development and Commercialization of iCo-008
|
Aug 19, 2019
|
iCo Therapeutics Inc. Announces Closing of $2.1 Million Private Placement Financing
|
Feb 21, 2019
|
iCo Therapeutics Inc. Announces $1.25 Million Non-Brokered Private Placement Financing
|
Nov 21, 2018
|
iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study
|
Nov 13, 2018
|
iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board
|
Sep 14, 2018
|
iCo Therapeutics Announces Additional Positive Pharmacokinetic Results
|
Jun 27, 2018
|
iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study
|
Jun 21, 2018
|
iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment
|
Jun 7, 2018
|
iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial
|
May 7, 2018
|
iCo Therapeutics Announces Year End 2017 Financial Results
|
|
1 - 10 of 27 results
|
|
 |
|
|
|
Share This Company Profile |
|
|
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|